China Plans to Slap Astronomical Fines on GSK
China’s Public Security Ministry has said that they should learn from the practice of other countries and impose 'astronomical fines' in corruption cases
China’s Public Security Ministry has in a statement said that it is considering an ‘astronomical’ fine on GlaxoSmithKline (GSK), which has been tangled in the corruption and bribery scandal
Singapore: In a bid to send out a strong statement, the Public Security Ministry in China has said on its official website that the country should learn from the practice of other nations and impose 'astronomical' fines in cases of bribery and corruption.
The country is now considering imposing huge fines against British drug maker GlaxoSmithKline (GSK) for fostering an aggressive work culture that encouraged employees to create and coordinate a bribery network to boost sales.
The ministry further added that it was increasingly clear that the alleged corrupt activity by GSK (China) was not the work of individual employees, but instead was co-ordinated by top management. This statement came from the ministry only a day after one-of-the-four arrested GSK China executives made shocking revelations to the police.
Mr Huang Hong, who is GSK China's general manager, said that the firm's corporate headquarters in Britain had set annual sales growth targets of up to 25 percent. In order to meet those targets, GSK China had linked employee salaries to sales volumes. Mr Hong also told the police that under the firms policies, workers could lose thousands of yuan per month if they did not meet their goals.
Related News
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance